The University of California, Davis, and University of Iowa Institutional Review Boards approved the protocol, which adhered to the tenets of the Declaration of Helsinki, and participants signed informed consent documents before testing. The medical records database from 1999 to 2002 was queried by using ICD-9 codes for visual loss, brain neoplasm, optic nerve drusen, pituitary tumor, anterior ischemic optic neuropathy, and cerebrovascular accident. One hundred and nine patients with visual field loss secondary to a neuro-ophthalmic disorder gave informed consent to participate in the study. Patients were seen either at the University of California, Davis, Neuro-ophthalmology Clinic or the University of Iowa Neuro-Ophthalmology Clinic. All subjects underwent neuro-ophthalmic examination, including intraocular pressure measurement. Patients had lesions of the optic nerve or chiasm, documented by magnetic resonance imaging or computed tomography, or they had objective evidence of an optic neuropathy. Optic neuropathy was defined as a decline in vision, color perception, or visual fields along with evidence of optic nerve swelling, and/or atrophic pallor. This optic neuropathy could be secondary to ischemia, compressive or infiltrative lesions, trauma, toxins or nutritional deficiencies, hereditary or congenital optic neuropathies, or increased intracranial pressure. The default visual field test for new patients in the neuro-ophthalmology clinic is Humphrey Visual Field Analyzer using SITA Standard 24-2 (SAP). The subjects’ charts were reviewed for stable visual field loss, reliable perimetry, and to exclude confounding diagnoses such as glaucoma or retinal disease. Patients with extensive diabetic retinopathy and/or previous laser treatments were also excluded. During the course of the study, some patients with prior visual field loss demonstrated normal visual fields. These patients were not excluded from the study. All patients had perimetry with both Humphrey SITA Standard 24-2 and Humphrey Matrix 24-2 performed in both eyes on the same day, with the exception of 11 patients who had one eye tested due to poor vision in the other eye. A total of 207 eyes were tested in the initial 109 patients. All patients underwent both SAP and Matrix testing. These fields were reviewed for reliability to exclude unreliable fields. Reliability criteria used consisted of a limit of 15% for false positives, 33% for false negatives and fixation losses for the SAP, and 33% for all three reliability indices for the Matrix. These percentages are the internal reliability thresholds used by the Humphrey SITA Standard 24-2 and Matrix 24-2. Healthy eyes of patients with unilateral neuro-ophthalmic disorders were also excluded. Only one eye was selected in patients with bilateral disease. If these patients had reliable fields from both eyes, the selection was based on alternating the better eye and worse eye based on the SAP mean deviation. After excluding unreliable visual fields, the final patient population consisted of one eye from 93 patients.
Table 1summarizes the characteristics of the patient sample.
To calculate the specificity of both perimeters, we recruited an additional 50 normal subjects by placing phone calls to individuals at random from the Iowa City phone book and by placing advertisements in a hospital newsletter. Normal subjects were included if they had (1) no history of eye disease except refractive error (no more optical correction than 5 D of sphere or 3 D of cylinder); (2) no history of diabetes mellitus or systemic arterial hypertension; (3) no history of ophthalmic surgery; and (4) a normal ophthalmic examination including 20/25 or better corrected Snellen acuity. The included subjects had either undergone a complete eye examination within 12 months before the study or were examined by an ophthalmologist on the day of testing to ensure normal ocular health. Normal subjects had a randomly chosen eye tested with both SAP and Matrix. The normal subject group’s mean age was 57 years (range, 45–73).